Observational studyClinical cancer research : an official journal of the American Association for Cancer Research2021
Abstract readObservational Study
In one paragraph
Observational study in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Correspondence to letter to the editor on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".Clinical and molecular hepatology · 2026Article
- Review
- MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer.NPJ precision oncology · 2025Review
- Liquid Biopsy in Solid Tumours: An Overview.Cytopathology : official journal of the British Society for Clinical Cytology · 2025Review
- Patients with Papillary Renal Cancer and Germline Duplication ofBiomedicines · 2025Article
- Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.Clinical and translational medicine · 2025Article
- Phosphorylation of MET Is Upregulated in Metastatic Sites of Renal Cell Carcinoma: Possible Role of MET and Hepatocyte Growth Factor Activation-Targeted Combined Therapy.Biomedicines · 2025Article
- The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer.Cell reports. Medicine · 2025Review
- Review
- Unveiling the Role of HGF/c-Met Signaling in Non-Small Cell Lung Cancer Tumor Microenvironment.International journal of molecular sciences · 2024Review
- The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Review
- Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer.Frontiers in oncology · 2024Review
- The Treatment of a New Entity in Advanced Non-small Cell Lung Cancer: MET Exon 14 Skipping Mutation.Current medicinal chemistry · 2024Review
- MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.Molecular oncology · 2023Article
- Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC WithJTO clinical and research reports · 2023Article
- [Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.Cancers · 2023Review
- Rare molecular subtypes of lung cancer.Nature reviews. Clinical oncology · 2023Review
- DEPDC1 as a crucial factor in the progression of human osteosarcoma.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Robin Guo *Thoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-1722-1742
Michael Offin *Thoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7959-3018
A Rose BrannonDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jason ChangDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrew ChowThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Lukas DelasosDepartment of Medicine, UConn Health, Farmington, Connecticut.ORCID 0000-0002-6409-2640
Jeffrey GirshmanDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0533-0423
Olivia WilkinsThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-5254-2130
Caroline G McCarthyThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Alex MakhninThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Christina FalconThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Kerry ScottNantomics Inc., Rockville, Maryland.
Yuan TianNantomics Inc., Rockville, Maryland.
Fabiola CecchiNantomics Inc., Rockville, Maryland.
Todd HembroughNantomics Inc., Rockville, Maryland.
Deepu AlexDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6136-296X
Ronglai ShenDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering, New York, New York.
Ryma BenayedDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-3754-0321
Bob T LiThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6661-8733
Charles M RudinThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5204-3465
Mark G KrisThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Maria E ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5801-3144
Paul PaikThoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Ahmet Zehir *Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-5406-4104
Alexander Drilon *Thoracic Oncology, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. drilona@mskcc.org.ORCID 0000-0001-6806-9061
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MInstitutional Career Development CoreKL2TR002385 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI YUAN-SHAN ZHU · 2017 to 2026
$13.3MSummer research experiences for medical students supervised by faculty mentorsR25CA020449 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Charlotte Eielson Ariyan · 1985 to 2026
$6.2MMOLECULAR BASIS OF SEX STEROID ACTION IN PROSTATE CANCERR21DK061004 · NIDDK · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI ZHU, YUAN-SHAN · 2004 to 2005
$336kNCATS NIH HHS KL2 TR002385NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R25 CA020449NCI NIH HHS T32 CA009207NIDDK NIH HHS R21 DK061004
Abstract
purposeMET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in EXPERIMENTAL
designWe performed hybrid capture-based DNA sequencing, targeted RNA sequencing, cell-free DNA sequencing, selected reaction monitoring mass spectrometry (SRM-MS), and immunohistochemistry on patient samples of
resultsSeventy-five of 168
conclusionsIn
Indexed as
AdultAgedAged, 80 and overBiomarkers, TumorDNA Mutational AnalysisDrug Resistance, NeoplasmExonsFemaleHumansLungLung NeoplasmsMaleMiddle AgedProgression-Free SurvivalProspective StudiesProtein Kinase InhibitorsBiomarkers, TumorMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-met
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.